Wolfe Research Reiterates Outperform on Celldex Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research has reiterated its 'Outperform' rating for Celldex Therapeutics, maintaining a price target of $51. This suggests confidence in the company's future performance.
September 25, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wolfe Research has reiterated its 'Outperform' rating for Celldex Therapeutics, maintaining a price target of $51. This suggests confidence in the company's future performance.
The reiteration of an 'Outperform' rating and a maintained price target of $51 by Wolfe Research indicates a positive outlook on Celldex Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100